Cell-Free DNA Testing Company Natera Announces $250M Follow-On Offering
Gunderson Dettmer represented client Natera, a global leader in cell-free DNA (cfDNA) testing, in its $250 million follow-on offering. Dedicated to oncology, women’s health, and organ health, Natera aims to make personalized genetic testing and diagnostics part of the standard of care to protect health.
Morgan Stanley, Goldman Sachs & Co. LLC, TD Cowen and Piper Sandler acted as joint book-running managers for the offering. Baird acted as the lead manager and Raymond James and Craig-Hallum acted as co-managers for the offering.
The Gunderson Dettmer deal team was co-led by Jeff Vetter and Ryan Gunderson and included Jeff Thacker, Daniel Reichert and Leanne Gould.